ArticlePsychedelic medicine (New Rochelle, N.Y.)2024
American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey.
Article in Psychedelic medicine (New Rochelle, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.Palliative medicine · 2026Article
- [Acceptance of psilocybin-assisted therapy in German-speaking countries].Der Nervenarzt · 2025Article
- Do undergraduates' views of psychedelics relate to the context for psychedelic use?Drug science, policy and law · 2025Article
- A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.Psychedelic medicine (New Rochelle, N.Y.) · 2025Article
- The Acceptability of Psychedelic-Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour.International journal of mental health nursing · 2025Article
- My Bad, You Got This: witnessing, therapist attitude and the synergy between psychedelics and inner healing intelligence in the treatment of trauma.Frontiers in psychology · 2025Article
- Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use.Frontiers in psychology · 2025Article
- Psychoanalytically informed MDMA-assisted therapy for pathological narcissism: a novel theoretical approach.Frontiers in psychiatry · 2025Article
- Review
- Patients' Experiences Discussing Psychedelics for Therapeutic Purposes with Physicians and Other Health Care Providers.Psychedelic medicine (New Rochelle, N.Y.) · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psilocybin, a classic hallucinogen, may eventually be approved by the United States Food and Drug Administration for treatment-resistant depression. However, we are aware of only one published national survey of American psychiatrists regarding their opinions about hallucinogens and hallucinogen-assisted therapy, conducted by our group in 2016. Here, we report a repeat survey, using virtually identical methods, assessing whether American psychiatrists display greater optimism about the therapeutic use of hallucinogens in 2022-23. Methods: We e-mailed our survey instrument to 1,000 randomly selected American Psychiatric Association members-250 resident-fellows and 750 attending psychiatrists-in late 2022 and early 2023. We calculated descriptive statistics and used a non-parametric trend test to compare the current survey responses with those from 2016. We also constructed a multivariate logistic regression model to assess attributes of respondents that predicted moderate/strong agreement with plans to incorporate hallucinogen-assisted therapy into their own practice. Results: The response rate was 13.1% ( Conclusions: Our data reveal a striking positive shift in attitudes toward the therapeutic potential of hallucinogens among American psychiatrists since 2016, with a majority of responding psychiatrists planning to incorporate hallucinogen-assisted therapy into their practice if regulatory approval is granted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.